| Literature DB >> 35369294 |
Kai'En Leong1,2, Luke Howard3,4, Francesco Lo Giudice3,5, Holly Pavey6, Rachel Davies3, Gulammehdi Haji3, Simon Gibbs4, Deepa Gopalan1,7.
Abstract
Aims: Pulmonary hypertension (PH) is dichotomized into pre- and post-capillary physiology by invasive catheterization. Imaging, particularly strain assessment, may aid in classification and be helpful with ambiguous hemodynamics. We sought to define cardiac MRI (CMR) feature tracking biatrial peak reservoir and biventricular peak systolic strain in pre- and post-capillary PH and examine the performance of peak left atrial strain in distinguishing the 2 groups compared to TTE. Methods andEntities:
Keywords: cardiac MRI (CMR); feature tracking (CMR-FT); left atrial strain (LA strain); post-capillary pulmonary hypertension; pre-capillary pulmonary hypertension; pulmonary hypertension
Year: 2022 PMID: 35369294 PMCID: PMC8968034 DOI: 10.3389/fcvm.2022.787656
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1CMR LA volumetric and deformation assessment. Combined CMR LAVi and peak LA strain multivariate AUC 0.98 for post-capillary PH diagnosis.
Baseline patient characteristics.
|
| |||
|---|---|---|---|
| Age (years) | 48 ± 17 | 71 ± 11 |
|
| Sex (%) | Male 6 (27%) | Male 12 (46%) | 0.237 |
| Female 16 (73%) | Female 14 (54%) | ||
| BMI (kg/m2) | 27.5 ± 7.4 | 33.1 ± 7.4 |
|
| Serum creatinine (μmol/L) | 77 ± 15 | 114 ± 74 |
|
| AF at TTE (%) | 0 | 15 (58%) |
|
| Any history of documented AF (%) | 1 (5%) | 20 (77%) |
|
| Clinical classification | Idiopathic PAH – 14 (64%) | SD – 1 (4%) |
|
| Functional class | |||
| ≤II | 6 (27%) | 5 (19%) | 0.732 |
| ≥III | 16 (73%) | 21 (81%) | |
| Medical therapy | Loop diuretics – 6 (27%) | Loop diuretics – 19 (73%) |
|
| Catheterization-CMR interval (days) | 3 (1–63) | 1 (0–7) | 0.154 |
| Catheterization-TTE interval (days) | 33 (1–110) | 36 (22–64) | 0.626 |
| TTE-CMR interval (days) | 18 (1–43) | 39 (22–78) |
|
PAH, pulmonary arterial hypertension; CTD, connective tissue disease; HIV, human immunodeficiency virus; CHD, congenital heart disease; SD, systolic dysfunction (LVEF < 50%); DD, diastolic dysfunction; MRA, mineralocorticoid receptor antagonist; ETRA, endothelin receptor antagonist (ambrisentan and macitentan); DOAC, direct oral anticoagulant; ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CCB, calcium channel blocker; PDE5i, phosphodiesterase type 5 inhibitor (sildenafil and tadalafil). The bold values indicate a p-value of ≤ 0.05.
Invasive haemodynamic parameters.
|
| |||
|---|---|---|---|
| PA systolic (mmHg) | 89 ± 21 | 65 ± 17 |
|
| PA diastolic (mmHg) | 36 ± 13 | 26 ± 6 |
|
| mPAP (mmHg) | 55 ± 14 | 42 ± 9 |
|
| mPAWP (mmHg) | 10 ± 3 | 22 ± 5 |
|
| mRAP (mmHg) | 9 ± 6 | 14 ± 5 |
|
| PVR (Wood units) | 11.7 (7.8–18.0) | 3.7 (2.4–5.7) |
|
| SaO2 (%) | 95.9 ± 2.7 | 95.3 ± 3.0 | 0.450 |
| SvO2 (%) | 68.0 ± 6.6 | 69.8 ± 8.7 | 0.419 |
| Stroke volume indexed (ml/m2) | 29 (25–33) | 31 (28–38) | 0.106 |
| Cardiac index (L/min/m2) | 2.0 (1.8–2.5) | 2.1 (1.9–2.6) | 0.282 |
| HR (bpm) | 80 ± 15 | 75 ± 11 | 0.227 |
The bold values indicate a p-value of ≤ 0.05.
TTE parameters.
|
| |||
|---|---|---|---|
| TR Vmax (m/s) | 4.2 ± 0.8 | 3.7 ± 0.5 |
|
| Transmitral E (cm/s) | 56 ± 19 | 96 ± 28 |
|
| Medial e' (cm/s) | 6 ± 2 | 6 ± 2 | 0.785 |
| Lateral e' (cm/s) | 11 ± 4 | 9 ± 3 | 0.223 |
| E/medial e' | 10.0 ± 3.9 | 17.9 ± 8.7 |
|
| E/lateral e' | 5.8 ± 2.7 | 11.1 ± 4.7 |
|
| Average E/e' | 7.9 ± 2.9 | 14.5 ± 6.3 |
|
| ePLAR (E/medial e') | 0.48 (0.29–0.59) | 0.22 (0.17–0.34) |
|
| Variant ePLAR (E/lateral e') | 0.79 (0.51–1.10) | 0.36 (0.27–0.47) |
|
| Variant ePLAR (average E/e') | 0.51 (0.39–0.76) | 0.25 (0.21–0.37) |
|
| LAVi (ml/m2) | 23 ± 7 | 45 ± 17 |
|
The bold values indicate a p-value of ≤ 0.05.
CMR volumetric and FT strain assessment.
|
| |||
|---|---|---|---|
| LAVi (ml/m2) | 25 ± 9 | 60 ± 22 |
|
| Peak LA strain (%) | 22.6 ± 8.4 | 9.0 ± 5.8 |
|
| RAVi (ml/m2) | 60 ± 21 | 61 ± 29 | 0.694 |
| Peak RA strain (%) | 18.8 ± 7.0 | 8.9 ± 5.5 |
|
| LA/RA volume ratio | 0.33 (0.29–0.65) | 1.0 (0.83–1.30) |
|
| LVEDVi (ml/m2) | 48 (43–54) | 64 (46–73) |
|
| LVESVi (ml/m2) | 17 (16–25) | 22 (15–30) | 0.178 |
| LV stroke volume indexed (ml/m2) | 30 (26–34) | 36 (29–43) |
|
| LVEF (%) | 62 (59–66) | 63 (59–67) | 0.656 |
| LV GLS (%) | −13.3 ± 3.2 | −13.4 ± 2.9 | 0.910 |
| RVEDVi (ml/m2) | 119 (97–136) | 76 (69–88) |
|
| RVESVi (ml/m2) | 82 (61–98) | 39 (31–50) |
|
| RV stroke volume indexed (ml/m2) | 39 (34–44) | 38 (30–50) | 0.885 |
| RVEF (%) | 35 ± 9 | 49 ± 9 |
|
| RVFWLS (%) | −10.1 ± 3.7 | −13.7 ± 3.1 |
|
| LVEDV/RVEDV ratio | 0.44 (0.32–0.56) | 0.78 (0.62–0.92) |
|
The bold values indicate a p-value of ≤ 0.05.
Figure 2Comparison of selected TTE and CMR discriminator AUC.
Comparison of predictive ability/AUC of 10 discriminator parameters with associated cut-points for post-capillary PH diagnosis.
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|
|
| ||||||
| ePLAR (E/medial e') | 0.84 (0.71–0.93) | ≤0.29 | 2.9 | 0.5 | 65% | 77% |
| Variant ePLAR (E/lateral e') | 0.89 (0.76–0.96) | ≤0.48 | 3.7 | 0.2 | 85% | 77% |
| Variant ePLAR (average E/e') | 0.88 (0.75–0.95) | ≤0.39 | 4.4 | 0.2 | 81% | 82% |
| TTE LAVi (ml/m2) | 0.89 (0.77–0.96) | >25 | 5.1 | 0.1 | 92% | 82% |
|
| ||||||
| Peak LA strain (%) | 0.92 (0.80–0.98) | <12 | – | 0.2 | 81% | 100% |
| CMR LAVi (ml/m2) | 0.96 (0.86–1.00) | >39 | 18.6 | 0.2 | 85% | 95% |
| LA/RA volume ratio | 0.91 (0.79–0.97) | >0.72 | 4.9 | 0.1 | 88% | 82% |
| LVEDV/RVEDV ratio | 0.87 (0.75–0.95) | >0.56 | 4.4 | 0.2 | 81% | 82% |
| RVFWLS (%) | 0.87 (0.74–0.95) | ≤-10.4 | 2.2 | 0.2 | 88% | 59% |
| RVEF (%) | 0.76 (0.62–0.87) | >42 | 4.2 | 0.3 | 77% | 82% |
All p < 0.001.
Figure 3Bland-Altman comparison of TTE and CMR non-indexed LAV. Shading represents ± SD. Dotted line indicates mean bias.
Figure 4Biatrial pressure-volumetric/strain correlation in entire cohort.
Figure 5mRAP-mPAP and mRAP-mPAWP relationships in post-capillary PH patients.